|
US2021106572A1
|
|
Use of pridopidine for the treatment of anxiety and depression
|
|
US2021030734A1
|
|
Method of treating amyotrophic lateral sclerosis with pridopidine
|
|
US2021093622A1
|
|
Use of pridopidine for the treatment of anxiety and depression
|
|
US2021052560A1
|
|
Use of pridopidine for treating functional decline
|
|
WO2020250234A1
|
|
Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof
|
|
WO2020188558A1
|
|
Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine
|
|
WO2020161707A1
|
|
Low dose pridopidine for parkinson's disease and other diseases associated with parkinsonism
|
|
WO2020110128A1
|
|
Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia
|
|
US2020093813A1
|
|
Use of pridopidine to improve cognitive function and for treating alzheimer's disease
|
|
US2019350915A1
|
|
Pridopidine for treating huntington's disease
|
|
AU2018326596A1
|
|
High concentration dosage forms of pridopidine
|
|
CN111278440A
|
|
Method of treating amyotrophic lateral sclerosis with pridopidine
|
|
CA3050700A1
|
|
Use of pridopidine for the treatment of fragile x syndrome
|
|
EP3512506A1
|
|
Use of pridopidine for treating rett syndrome
|
|
AU2017315783A1
|
|
Use of pridopidine for treating a subject with early stage huntington disease
|
